🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing around the world, with data suggesting over 82 million infections annually. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options presently on offer.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Experts believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

Based on findings released by a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have shared hope. Having a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.